Impax, Tolmar in Development and Supply Pact

Impax Laboratories and Tolmar have entered a multi-product agreement for the development, supply and distribution of alternative dosage form products. The products and terms were not disclosed.

“We are excited to expand our relationship with Tolmar on these products. It represents an ideal extension of our initial product agreement,” said Larry Hsu, Ph.D., president and chief executive officer of Impax Laboratories. “In the past two years, we have entered into four distinct partnerships for alternative dosage form products as we continue to execute our strategy of diversifying our product base. Our business development activities will continue to focus on delivering growth from high-value products, technologies, and businesses in complementary dosage forms.”

Mike Duncan, chief executive officer of Tolmar, said, “We are very pleased with this agreement. Tolmar is once again recognized as a key player in the specialty pharma space. This agreement is aligned with our long-term corporate strategy and we firmly believe that Impax Laboratories is the right partner for these products. Tolmar is continuously expanding its facilities and employee base to meet current and future needs.”